Ultimately, these “2nd generation” CAR constructs have displayed unprecedented clinical efficacy, particularly when targeted against CD19 expressing B-cell lymphomas and leukemias and against B-cell maturation antigen (BCMA)-expressing multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.